RxDoctor Payments Data

Porsha Melcher

Podiatrist · Sugar Land, TXNPI 1437568136

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Paragon 28, Inc. at 30.1% of the total. Reporting peaked in 2022 at $5,693 and has fallen 65.1% since, to $1,984 in 2025.

$14,128in general payments, 2019–2025

Across 94 payments — averaging $150.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$4K
  • Peerless Surgical Inc.$3K
  • Organogenesis Inc.$2K
  • Arthrex$2K
  • Mimedx Group, Inc.$1K
  • Linvatec Corporation$815
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$7,87256%
  • Food & beverage$3,85527%
  • Education$2,40017%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,128 in reported general payments places this provider in the 85th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$3,130
Medicare patients
22
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox245$11,496
Clotrimazole202$2,430
Methylprednisolone62$703
Ammonium Lactate19$510
Terbinafine Hcl34$492
Ketoconazole48$461
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$413
Doxycycline Hyclate31$268
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$224
Gabapentin15$98

Paid to pharmacies, not to this prescriber.

Other podiatrist in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →